Abstract 110P
Background
Conversion therapy is an important treatment for patients with initial unresectable metastatic colorectal cancer(mCRC) to achieve radical resection. Circulating tumor cells (CTC) are one of the important liquid biopsy methods. There is no study to explore their clinical value in predicting the efficacy. The aim of this study is to explore the value of the number and morphology of CTC in predicting the efficacy of conversion therapy in initial unresectable mCRC patients.
Methods
This study prospectively collected eligible patients with initially unresectable mCRC who were initially diagnosed in Zhongshan Hospital from November 2020 to June 2021. At baseline, after treatment, and before and after conversion resection, multi-point blood sampling was performed. CTC detection using ChimeraX ® Platform; Morphological typing is based on the CTC morphological data of 2083 patients with colorectal cancer who underwent CTC detection in Zhongshan Hospital. Cell Profiler is used for cell feature assignment, clustering and typing.
Results
A total of 126 eligible patients with mCRC participated in this study. According to morphology, CTC can be divided into four morphological types: T1-T4. All 126 patients underwent baseline CTC testing, and 103 patients underwent CTC testing after conversion therapy. After conversion therapy, the positive rate and detection number of CTC significantly decreased (85.7% vs 60.2%, 1.71 vs 1.15, P=0.0052); The detection number of T3 and T4 subtypes significantly decreased (T3: 0.87 vs 0.52, P=0.0026, T4: 0.25 vs 0.06, P<0.0001). The objective response rate was significantly correlated with the baseline number of CTCs (69.8% vs 50.8%, P=0.029), but not significantly with the number of CTCs after treatment. The objective response rate of patients with T3T4 dominance was significantly higher than that of patients with T1T2 dominance (67.6% vs 47.1%, P=0.042). The number of CTC was correlated with patient progression free survival, and baseline CTC positive patients had a worse prognosis (P=0.0012).
Conclusions
The number and morphology of CTCs have good therapeutic and prognostic value for patients with initial unresectable mCRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract